These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20215378)

  • 1. Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease.
    Shimura M; Yasuda K
    Br J Ophthalmol; 2010 Mar; 94(3):381-3. PubMed ID: 20215378
    [No Abstract]   [Full Text] [Related]  

  • 2. Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion.
    Leung LS; Silva RA; Blumenkranz MS; Flynn HW; Sanislo SR
    Ophthalmic Surg Lasers Imaging; 2012 Jul; 43 Online():e73-9. PubMed ID: 22823029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of bevacizumab as the primary treatment for retinal vein occlusions.
    Figueroa MS; Contreras I; Noval S; Arruabarrena C
    Br J Ophthalmol; 2010 Aug; 94(8):1052-6. PubMed ID: 20679089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
    Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
    Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion.
    Kim KS; Chang HR; Song S
    Acta Ophthalmol; 2008 Dec; 86(8):925-7. PubMed ID: 18494740
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion.
    Parveen S; Narayanan R; Sambhav K; Bhatia K
    Retina; 2010 Sep; 30(8):1324-5; author reply 1325. PubMed ID: 20827152
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
    Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2009; 29(10):1396-403. PubMed ID: 19898177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
    Sonoda Y; Arimura N; Shimura M; Sakamoto T
    Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute vision loss after intravitreal injection of bevacizumab (avastin) associated with ocular ischemic syndrome.
    Huang ZL; Lin KH; Lee YC; Sheu MM; Tsai RK
    Ophthalmologica; 2010; 224(2):86-9. PubMed ID: 19707032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW
    Ophthalmologica; 2011; 225(3):150-4. PubMed ID: 21150231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Ophthalmologica; 2009; 223(2):124-7. PubMed ID: 19088494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
    Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.